Cannabis Bioscience International Holdings, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended May 31, 2025 was Clinical Trials at $301,731, 100% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Feb 28, 2026
|
FY 2025
May 31, 2025
|
FY 2024
May 31, 2024
|
|---|---|---|---|
| Revenue |
0
|
0
|
0
|
| Clinical Trials |
—
|
0
+41.1%
share 99.6%
|
0
share 85.9%
|
| Consulting Fees |
—
|
—
|
0
share 11.5%
|
| Seminar Fees |
—
|
—
|
0
share 0.8%
|
| Merchandise |
—
|
0
-70.7%
share 0.4%
|
0
share 1.8%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- CBIH (OTC)
- Fiscal year ends
- May 31
- Incorporated in
- CO
- Headquarters
- Yantis, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1411057
- Former names
- CHINA INFRASTRUCTURE CONSTRUCTION Corp (until Aug 24, 2022); FIDELITY AVIATION CORP (until Sep 15, 2009)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.